2026 Interim Report
Filed with HKEX · Stock code 2197 · · 77 pages · English
Clover Biopharmaceuticals Ltd. on 6ix
Earlier from Clover Biopharmaceuticals
- Clover Announces Positive Phase 2 Clinical Data for RSV + hMPV ± PIV3 Respiratory Combination Vaccine Candidates in Older Adults
- Clover Announces Additional Positive U.S. Phase I Clinical Data for RSV Re-Vaccination in Older Adults
- Clover Initiates Phase 2 Clinical Trial for RSV + hMPV ± PIV3 Respiratory Combination Vaccine Candidates
- Clover Appoints Nicholas Jackson, Ph.D., as President of Global R&D and Alliances
- Clover Announces Positive Phase I Clinical Data for RSV-hMPV-PIV3 Combination Vaccines and for RSV Re-Vaccination in Older Adults
Later from Clover Biopharmaceuticals
All Clover Biopharmaceuticals news releasesFollow Clover Biopharmaceuticals into a list and get an email when it puts out news.
Follow Clover Biopharmaceuticals